Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease (OPERA)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: January 12, 2011
Last updated: February 8, 2015
Last verified: February 2015

Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.

Condition Intervention Phase
Crohn's Disease
Drug: PF-00547659 SC injection
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Crohn's Disease Activity Index (CDAI) 70 response rate at week 8 or week 12 (between the investigational product group and the placebo group). [ Time Frame: 16 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability of PF-00547659 dose levels versus placebo: the frequency of treatment adverse events, withdrawal due to adverse events, and serious adverse events (SAEs) will be reported. [ Time Frame: 40 months ] [ Designated as safety issue: Yes ]
  • Percent of subjects with a CDAI remission (CDAI <150), CDAI 70 and CDAI 100 responses Weeks 2 through 12. [ Time Frame: 16 months ] [ Designated as safety issue: No ]
  • Immunogenicity assessments of antidrug antibodies (ADAs). [ Time Frame: 40 months ] [ Designated as safety issue: Yes ]
  • The PK of total PF-00547659 will be characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life will be estimated using data pooled from both typical and additional PK groups. [ Time Frame: 40 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 240
Study Start Date: April 2011
Estimated Study Completion Date: December 2015
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo-SC Injection Drug: PF-00547659 SC injection
Placebo delivered SC, 3 doses separated by 4 weeks
Experimental: Drug Dose level 1- SC injection Drug: PF-00547659 SC injection
Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
Experimental: Drug Dose level 2-SC injection Drug: PF-00547659 SC injection
Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
Experimental: Drug Dose level 3- SC injection Drug: PF-00547659 SC injection
Drug dose level 3 delivered SC, 3 doses separated by 4 weeks


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have failed or are intolerant to anti-TNFs and/or immunosuppressants (AZA, 6-MP, and/or MTX).
  • hsCRP greater than 3mg/L
  • Ulcerations demonstrated by colonoscopy performed during screening or 8 weeks prior to screening

Exclusion Criteria:

  • Pregnant or breast feeding
  • Short bowel syndrome due to multiple small bowel resections
  • Presence of a stoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01276509

  Show 146 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT01276509     History of Changes
Other Study ID Numbers: A7281006, 2010-023437-30, OPERA
Study First Received: January 12, 2011
Last Updated: February 8, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Crohn's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn's Disease Activity Index (CDAI)

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases processed this record on May 29, 2015